TY - JOUR
T1 - An update on the management of low-risk differentiated thyroid cancer
AU - Lamartina, Livia
AU - Leboulleux, Sophie
AU - Terroir, Marie
AU - Hartl, Dana
AU - Schlumberger, Martin
N1 - Publisher Copyright:
© 2019 Society for Endocrinology.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Low-risk papillary cancers, which represent the vast majority of thyroid cancers diagnosed today, do not require aggressive treatment or follow-up. Initial treatment consists of a total thyroidectomy without prophylactic lymph node dissection. A hemithyroidectomy is an alternative in some patients with an intrathyroidal tumor and with a normal contralateral lobe at pre-operative neck ultrasonography. The use of post-operative radioiodine should be restricted to selected patients. Follow-up at 6-18 months is based on serum thyroglobulin (Tg), Tg-antibody determination and neck ultrasonography. In the absence of any abnormality (excellent response to treatment), the risk of recurrence is extremely low and follow-up may consist of serum TSH monitor ing that is maintained in the normal range, and a Tg and Tg-antibody titer determinati on every year. There is no need for referral to a specialized center. In patients wi th detectable serum Tg or detectable Tg antibodies, the trend over time of these marke rs on levothyroxine treatment will dictate subsequent follow-up: A decreasing trend is reassuring, but an increasing trend should lead to imaging, starting with neck ultrasonography.
AB - Low-risk papillary cancers, which represent the vast majority of thyroid cancers diagnosed today, do not require aggressive treatment or follow-up. Initial treatment consists of a total thyroidectomy without prophylactic lymph node dissection. A hemithyroidectomy is an alternative in some patients with an intrathyroidal tumor and with a normal contralateral lobe at pre-operative neck ultrasonography. The use of post-operative radioiodine should be restricted to selected patients. Follow-up at 6-18 months is based on serum thyroglobulin (Tg), Tg-antibody determination and neck ultrasonography. In the absence of any abnormality (excellent response to treatment), the risk of recurrence is extremely low and follow-up may consist of serum TSH monitor ing that is maintained in the normal range, and a Tg and Tg-antibody titer determinati on every year. There is no need for referral to a specialized center. In patients wi th detectable serum Tg or detectable Tg antibodies, the trend over time of these marke rs on levothyroxine treatment will dictate subsequent follow-up: A decreasing trend is reassuring, but an increasing trend should lead to imaging, starting with neck ultrasonography.
KW - Hemithyroidectomy
KW - Low-risk thyroid cancer
KW - Neck ultrasonography
KW - Radioactive iodine
KW - Thyroglobulin
KW - Total thyroidectomy
UR - http://www.scopus.com/inward/record.url?scp=85074921582&partnerID=8YFLogxK
U2 - 10.1530/ERC-19-0294
DO - 10.1530/ERC-19-0294
M3 - Review article
C2 - 31484161
AN - SCOPUS:85074921582
SN - 1351-0088
VL - 26
SP - R597-R610
JO - Endocrine-Related Cancer
JF - Endocrine-Related Cancer
IS - 11
ER -